

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Medicis Pharmaceutical Corporation	08/23/2013
RECEIVING PARTY DATA	
Name:	Thesan Pharmaceuticals, Inc.
Street Address:	392 Camino de Estrella
City:	San Clemente
State/Country:	CALIFORNIA
Postal Code:	92672
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	8242286
Application Number:	13945622
Patent Number:	8524761
Patent Number:	7615230
Patent Number:	8409595
Application Number:	13783936
Patent Number:	7622610
Patent Number:	7981936
Patent Number:	7964612
Patent Number:	8455512
Application Number:	13864457
CORRESPONDENCE DATA	
Fax Number:	2123910525
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2122780400

CH \$440.00 8242286

Email: jwhite@cooperdunham.com
Correspondent Name: Cooper & Dunham LLP
Address Line 1: 30 Rockefeller Plaza
Address Line 4: New York, NEW YORK 10112

ATTORNEY DOCKET NUMBER:	5128/85128/JPW/PEA
NAME OF SUBMITTER:	Cindy S. Shu
Signature:	5128-85128/CSS/for John P White
Date:	09/25/2013

Total Attachments: 9

source=(5128) 85128 - Assignment from Medicis to Thesan_Page_1#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_2#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_3#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_4#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_5#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_6#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_7#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_8#page1.tif
source=(5128) 85128 - Assignment from Medicis to Thesan_Page_9#page1.tif

PATENT ASSIGNMENT

WHEREAS: MEDICIS PHARMACEUTICAL CORPORATION, a Delaware corporation ("**ASSIGNOR**") is the owner of certain patents as defined herein; and


WHEREAS: THESAN PHARMACEUTICALS, INC., a Delaware corporation ("**ASSIGNEE**") is desirous of acquiring from ASSIGNOR, ASSIGNOR'S entire right, title, and interest in, to, and under those certain patents.

NOW, THEREFORE, for good and valuable consideration provided by ASSIGNEE to ASSIGNOR, the receipt of which is hereby acknowledged, and in accordance with the terms and conditions of that certain ASSET PURCHASE AGREEMENT between ASSIGNOR and ASSIGNEE effective August 23, 2013 (the "Asset Purchase Agreement"), ASSIGNOR hereby sells, assigns, and transfers to ASSIGNEE, its successors, legal representatives, or assigns, ASSIGNOR'S full and exclusive right, title, and interest in, to, and under those patents and patent applications identified in Exhibit A hereto (which contains every patent application and patent listed in Exhibit B to the Asset Purchase Agreement), and any patent application or patent that claims priority to or shares a common claim of priority with one or more of such listed patents or patent applications including all additions, confirmation patents, certificate of correction, divisionals, continuations, continuations-in-part with respect to any such patent applications, extensions, provisionals, any patents issuing therefrom, patents of addition, reissues, re-examinations, registrations, renewals, substitutions, and supplementary protection certificates and other extensions of any such patents or patent applications.

[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]

This ASSIGNMENT shall be binding upon ASSIGNOR'S heirs, executors, administrators, successors, and/or assigns.

MEDICIS PHARMACEUTICAL CORPORATION


By: 

Name: Howard Schiller

Title: EVP and Chief Financial Officer

Accepted by:

THESAN PHARMACEUTICALS, INC.

By: 

Name: T. G. FOULKES

Title: CEO

EXHIBIT A

SCD-1 Portfolio

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
	Phenoxy-pyrrolidine Derivative and its use and Compositions			
AU	F-MRX-SCD01. P20070808. AUN00	2008285255/ 2008285255	Granted	08/08/2007
AU	F-MRX-SCD01. P20070808. AUD01	2012216754	Pending	08/08/2007
BR	F-MRX-SCD01. P20070808. BRN00	PI0815048-6	Pending	08/08/2007
CA	F-MRX-SCD01. P20070808. CAN00	2695664	Allowed (Final Fees Due Aug. 22, 2013)	08/08/2007
CN	F-MRX-SCD01. P20070808. CNN00	200880111278 (Published as 101821234)	Pending	08/08/2007
EPC	F-MRX-SCD01. P20070808. EPN00	8788986.1 / 2173711	Granted (validated in contracting states)	08/08/2007
FR	F-MRX-SCD01. P20070808. FRN00	8788986.1 / 2173711	Granted	08/08/2007
DE	F-MRX-SCD01. P20070808. DEN00	8788986.1 / 602008003586.7- 08	Granted	08/08/2007
IN	F-MRX-SCD01. P20070808. INN00	765/DELNP/2010	Pending	08/08/2007
IT	F-MRX-SCD01. P20070808. ITN00	8788986.1 / 2173711	Granted	08/08/2007

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
JP	F-MRX-SCD01. P20070808. JPN00	2010-519537 / 5239001	Granted	08/08/2007
JP	F-MRX- SCD01.P20070808. JPD01	2013-043265	Pending	08/08/2007
KR	F-MRX-SCD01. P20070808. KRN00	2010-7001820 / 10-1189189	Granted	08/08/2007
ES	F-MRX-SCD01. P20070808. ESN00	8788986.1 / 2352098	Granted	08/08/2007
GB	F-MRX-SCD01. P20070808. GBN00	8788986.1 / 2173711	Granted	08/08/2007
USA	F-MRX-SCD01. P20070808. USN00	12/670,010 / 8,242,286	Granted	08/08/2007
USA	F-MRX-SCD01. P20070808. USC02	13/945,622	Pending	08/08/2007
USA	F-MRX-SCD01. P20070808. USC01	13/549,299 / 8,524,761	Application to Issue 09/03/2013	08/08/2007
USA	F-MRX-SCD01. P20070808. USP00	60/954,593	Expired	08/08/2007

ACAT Portfolio

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
"Compositions and Methods for Decreasing Sebum Production"				
CA	F-MRX-CAT01. P19940831. CAN00	2157142	Granted	08/31/1994
EP	F-MRX-CAT01. P19940831. EPN00	95305594.4 / 0699439	Granted/ validated in contracting states	08/31/1994
DK	F-MRX-CAT01. P19940831. DKN00	95305594.4 / 699439	Granted	08/31/1994
FR	F-MRX-CAT01. P19940831. FRN00	95305594.4 / 699439	Granted	08/31/1994
DE	F-MRX-DET01. P19940831. DEN00	95305594.4 / 69512589.3	Granted	08/31/1994
IE	F-MRX-CAT01. P19940831. IEN00	95305594.4 / 699439	Granted	08/31/1994
IT	F-MRX-CAT01. P19940831. ITN00	95305594.4 / 699439	Granted	08/31/1994
JP	F-MRX-CAT01. P19940831. JPN00	1995-242297 / 3266473	Granted	08/31/1994
MX	F-MRX-CAT01. P19940831. MXN00	PA/a/1995/003681 / 211892	Granted	08/31/1994
NL	F-MRX-CAT01. P19940831. NLN00	95305594.4 / 699439	Granted	08/31/1994
ES	F-MRX-CAT01. P19940831. ESN00	95305594.4 / 699439 (ES2136252)	Granted	08/31/1994
SE	F-MRX-CAT01. P19940831. SEN00	95305594.4 / 699439	Granted	08/31/1994
CH	F-MRX-CAT01. P19940831. CHN00	95305594.4 / 699439	Granted	08/31/1994

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
GB	F-MRX-CAT01. P19940831. GBN00	95305594.4 / 699439	Granted	08/31/1994
USA	F-MRX-CAT01. P19940831. USN00	08/298,735 / 6,133,326	EXPIRED	08/31/1994
USA	F-MRX-CAT01. P19940831. USC01	09/536,480 / 6,271,268	EXPIRED	08/31/1994
"Methods Employing Malonamide-Type ACAT Inhibitors"				
AR	F-MRX-CAT02. P20031009. ARN00	P040103633	Pending	10/09/2003
AU	F-MRX-CAT02. P20031009. AUN00	2004280134	Granted	10/09/2003
CA	F-MRX-CAT02. P20031009. CAN00	2541814	Granted	10/09/2003
CN	F-MRX-CAT02. P20031009. CNN00	200480029467.3	Granted	10/09/2003
EP	F-MRX-CAT02. P20031009. EPN00	4769499.7/ 1673077	Granted / validated in contracting states	10/09/2003
DE	F-MRX-CAT02. P20031009. DEN00	4769499.7 / 602004016874.2	Granted	10/09/2003
DK	F-MRX-CAT02. P20031009. DKN00	4769499.7/ 1673077	Granted	10/09/2003
ES	F-MRX-CAT02. P20031009. ESN00	4769499.7/ 1673077 (ES2313065)	Granted	10/09/2003
FI	F-MRX-CAT02. P20031009. FIN00	4769499.7 / 1673077	Granted	10/09/2003
FR	F-MRX-CAT02. P20031009. FRN00	4769499.7 / 1673077	Granted	10/09/2003
IN	F-MRX-CAT02. P20031009. INN00	1280/DELNP/2006 / 237125	Granted	10/09/2003
IN	F-MRX-CAT02.	5910/DELNP/2009	Pending	10/09/2003

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
	P20031009. IND01			
IE	F-MRX-CAT02. P20031009. IEN00	4769499.7 / 1673077	Granted	10/09/2003
IT	F-MRX-CAT02. P20031009. ITN00	4769499.7 / 1673077	Granted	10/09/2003
KR	F-MRX-CAT02. P20031009. KRN00	2006-7006717	Granted	10/09/2003
MX	F-MRX-CAT02. P20031009. MXN00	PA/a/2006/003960 / 261368	Granted	10/09/2003
NL	F-MRX-CAT02. P20031009. NLN00	4769499.7 / 1673077	Granted	10/09/2003
SE	F-MRX-CAT02. P20031009. SEN00	4769499.7 / 1673077	Granted	10/09/2003
GB	F-MRX-CAT02. P20031009. GBN00	4769499.7 / 1673077	Granted	10/09/2003
USA	F-MRX-CAT02. P20031009. USN00	10/958,306 / 7,615,230	Granted	10/09/2003
USA	F-MRX-CAT02. P20031009. USC01	12/568,763 / 8,409,595	Granted	10/09/2003
USA	F-MRX-CAT02. P20031009. USC02	13/783,936	Pending	10/09/2003
USA	F-MRX-CAT02. P20031009. USP00	60/509,984	Expired	10/09/2003
"Crystalline ACAT Inhibitor"				
AR	F-MRX-CAT02. P20050224. ARN00	P060100660	Pending	02/25/2005
AU	F-MRX-CAT02. P20050224. AUN00	2006217529 / 2006217529	Granted	02/25/2005
BR	F-MRX-CAT02. P20050224. BRN00	P106140289	Pending	02/25/2005
CA	F-MRX-CAT02.	2598962 /	Granted	02/25/2005

Country	Medicis Ref.	App No./ Patent No.	Status	Priority
	P20050224. CAN00	2598962		
EPC	F-MRX-CAT02. P20050224. EPN00	6710501.5	Pending	02/25/2005
JP	F-MRX-CAT02. P20050224. JPN00	2006-46629	Granted	02/25/2005
KR	F-MRX-CAT02. P20050224. KRN00	2007-7019267	Granted	02/25/2005
MX	F-MRX-CAT02. P20050224. MXN00	MX/a/2007/010374 / 291508	Granted	02/25/2005
RU	F-MRX-CAT02. P20050224. RUN00	2007132010	Granted	02/25/2005
RU	F-MRX-CAT02. P20050224. RUD01	2010111337	Pending	02/25/2005
USA	F-MRX-CAT02. P20050224. USN00	11/354,486 / 7,622,610	Granted	02/25/2005
USA	F-MRX-CAT02. P20050224. USC01	12/577,993 / 7,981,936	Granted	02/25/2005
USA	F-MRX-CAT02. P20050224. USP00	60/655,758	Expired	02/25/2005

ALK-5 Portfolio

Country	Medicis Ref.	App. No. / Patent No.	Status	Priority
"Therapeutic Pyrazolyl Thienopyridines"				
AR	F-MRX-ALK01. P20061016. ARN00	70104581	Pending	10/16/2003
CA	F-MRX-ALK01. P20061016. CAN00	2666603	Granted	10/16/2003
EPC	F-MRX-ALK01. P20061016. EPN00	7825309.3	Granted	10/16/2003
EPC	F-MRX-ALK01. P20061016. EPD01	12006019.9	Pending	10/16/2003
IN	F-MRX-ALK01. P20061016. INN00	2162/DELNP/2009	Pending	10/16/2003
JP	F-MRX-ALK01. P20061016. JPN00	2009-532905	Pending	10/16/2003
USA	F-MRX-ALK01. P20061016. USN00	11/871,311 / 7,964,612	Granted	10/16/2003
USA	F-MRX-ALK01. P20061016. USC01	13/112,520 / 8,455,512	Granted	10/16/2003
USA	F-MRX-ALK01. P20061016. USC01	13/864,457	Pending	10/16/2003
USA	F-MRX-ALK01. P20061016. USP00	60/851,982	Expired	10/16/2003